Saar Gill, MD, PhD
Assistant Professor of Medicine
Director, Gill Laboratory, Center for Cellular Immunotherapies
Saar Gill obtained his medical degree from the University of Melbourne in Australia in 1999. He underwent internal medicine training at St Vincent's Hospital in Melbourne, followed by haematology training at the Peter MacCallum Cancer Centre and at the Royal Melbourne Hospital, which he completed in 2008. In 2008 he became a post-doctoral fellow at the laboratory of Robert Negrin at Stanford University, where he studied adoptive cellular therapy with NK cells. In 2011 Dr. Gill moved to the University of Pennsylvania where he did a BMT and Cellular Therapy fellowship under Dr David Porter, and started working in the laboratory with Dr. Michael Kalos on chimeric antigen receptor T cells for the treatment of acute myeloid leukemia (AML). In 2012 he became an Instructor of Medicine in the Division of Hematology-Oncology at the Perelman School of Medicine. In 2013 the Translational group split from the Correlative Sciences group and became the Gill laboratory. The overarching goals of the Gill Laboratory are to produce effective and safe CAR T cells for the treatment of hematologic malignancies such as leukemia and lymphoma.
Dr. Gill's research interests include: Human T cell immunology, allogeneic transplanation-related correlative sciences including graft-versus-host disease, the tumor microenvironment, and primarily, adoptive cellular therapy for the treatment of malignancy.